⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALZN News
Alzamend Neuro, Inc. Common Stock
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
prnewswire.com
ALZN
Form 8-K
sec.gov
ALZN
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
prnewswire.com
ALZN
Form 8-K
sec.gov
ALZN
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
prnewswire.com
ALZN